Related Experiment Videos
Minimizing risk of adverse reactions to mydriatic agents in binocular indirect ophthalmoscopy
Abstract:
To minimize the risk of adverse side effects from mydriatics during binocular indirect ophthalmoscopy, a procedure was developed which intentionally starts with a dose significantly less than an ED99. Using a clinically effective diameter of greater than 7 mm as a criterion, I found that 1 drop of 0.5% tropicamide (T) constituted an ED74 (N = 46). When 1 drop of 2.5% phenylephrine (P) was added, this increased to an ED93 (N = 27). If present results can be generalized, then 1 drop of T, supplemented at 30 minutes with 1 drop of P, if necessary, should produce satisfactory dilatation in approximately 90% of the subjects.
Insights
This study optimized mydriatic eye drops for indirect ophthalmoscopy. A combination of tropicamide and phenylephrine eye drops achieved satisfactory pupil dilation in about 90% of subjects, minimizing side effects.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Mydriatics are used for ophthalmoscopy but can cause adverse effects.
- Minimizing side effects while ensuring adequate pupil dilation is crucial.
Purpose of the Study:
- To develop a mydriatic regimen for binocular indirect ophthalmoscopy with reduced adverse effects.
- To determine the efficacy of a reduced-dose tropicamide and phenylephrine combination for achieving adequate pupil dilation.
Main Methods:
- A stepwise approach using reduced doses of mydriatics was employed.
- One drop of 0.5% tropicamide was administered initially.
- One drop of 2.5% phenylephrine was added if necessary after 30 minutes.
- Clinically effective pupil diameter was defined as greater than 7 mm.
Main Results:
- A single drop of 0.5% tropicamide achieved 74% effective dilation (ED74) in 46 subjects.
- Adding 2.5% phenylephrine increased efficacy to 93% (ED93) in 27 subjects.
- The combined regimen demonstrated high efficacy for pupil dilation.
Conclusions:
- A strategy of one drop of tropicamide, supplemented with phenylephrine if needed, can achieve satisfactory pupil dilation in approximately 90% of patients.
- This approach may minimize the risk of adverse effects associated with higher mydriatic doses.